Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study

Clinical Therapeutics

Volumn 24, Issue 9, 2002, Pages 1426-1438

  Dailey III, George E ^a   Mohideen, Pharis ^b   Fiedorek, Fred T ^b  

^a SCRIPPS CLINIC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Diabetes; Glyburide; Glyburide metformin tablets; HDL C; LDL C; Lipids; Metformin; Triglycerides

Indexed keywords

GLIBENCLAMIDE PLUS METFORMIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; TABLET; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036749762     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80046-7     Document Type: Article

References (39)

1. 2001 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2000:1-32.
2. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes in the United States, Atlanta, Ga: Centers for Disease Control and Prevention; 1998.
3. Facts About Heart Failure. Bethesda, Md: National Heart, Lung, and Blood Institute, National Institutes of Health; 1997:1-10. Publication no. 95-923.
4. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339:229-234.
5. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care. 1998;21:1167-1172.
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary. Bethesda, Md: National Institutes of Health; 2001:1-28. Publication no. 01-3670.
7. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43:960-967.
8. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001; 16 1:397-405.
9. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care. 1998;21:1236-1239.
10. The DECODE Study Group. European Diabetes Epidemiology Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617-621.
11. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
12. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124(Suppl):S11-S20.
13. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
14. Manley SE, Stratton IM, Cull CA, et al, for the UK Prospective Diabetes Study Group. Effects of three months' diet after diagnosis of type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). Diabet Med. 2000;17:518-523.
15. Fagot-Campagna A, Rolka DB, Beckles GL, et al. Prevalence of lipid abnormalities, awareness, and treatment in U.S. adults with diabetes. Diabetes. 2000;49 (Suppl 1):A79. Abstract 318PP.
16. Goldberg RB, Mellies MJ, Sacks FM, et al, for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 1998;98:2513-2519.
17. American Diabetes Association Position Statement. Management of dyslipidemia in adults with diabetes. Diabetes Care. 2002;25(Suppl 1):S74-S77.
18. Clark CM Jr. Oral therapy in type 2 diabetes: Pharmacological properties and clinical use of currently available agents. Diabetes Spectrum. 1998;11:211-221.
19. Simonson DC, Kourides IA, Feinglos M, et al, for the Glipizide Gastrointestinal Therapeutic System Study Group. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care. 1997;20:597-606.
20. Bayraktar M, Van Thiel DH, Adalar N. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care. 1996;19:252-254.
21. Hillebrand I, Boehme K, Frank G, et al. The effects of the alpha-glucosidase inhibitor BAY g 5421 (acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man. Res Exp Med (Berl). 1979;175:81-86.
22. Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia. 2000;43:278-284.
23. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study. Am J Med. 2001;111:10-17.
24. Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab. 1999;1:165-172.
25. DeFronzo RA, Goodman AM, for the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
26. Actos [package insert]. Lincolnshire, Ill: Takeda Pharmaceuticals America, Inc; 2001.
27. Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24:308-315.
28. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996;81:4059-4067.
29. 1c in first-line treatment of type 2 diabetes. Diabetes. 2000;49(Suppl 1):A107. Abstract 432P.
30. 1c response. Diabetes. 2000;49 (Suppl 1):A356. Abstract 1494PO.
31. Garber A, Davidson J, Anderson R, Piper BA. Incidence of reported gastrointestinal and hypoglycemic symptoms with metformin/glyburide tablets as first-line therapy in type 2 diabetes. Diabetes. 2000;49(Suppl 1):A357. Abstract 1498PO.
32. Rosenstock J, Donovan D, Piper B. Effect of metformin/glyburide tablets on post-prandial plasma glucose in type 2 diabetes. Diabetes. 2000;49(Suppl 1):A364. Abstract 1528PO.
33. Donovan D, Rosenstock J, Mooradian A, Henry D. Effect of metformin/glyburide tablets on fasting plasma glucose in type 2 diabetes. Diabetes. 2000;49(Suppl 1):A103. Abstract 415P.
34. Garber AJ, Larsen J, Schneider SH, et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacologic treatment for type 2 diabetes. Diabetes Obes Metab. 2002;4:201-208.
35. Draeger KE, Wernicke-Panten K, Lomp HJ, et al. Long-term treatment of type 2 diabetic patients with the new oral anti-diabetic agent glimepiride (Amaryl): A double-blind comparison with glibenclamide. Horm Metab Res. 1996;28:419-425.
36. Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2001.
37. Davidson PC, Sabbah HT, Steed RD, et al. Pioglitazone versus rosiglitazone therapy in randomized follow-up in patients previously treated with troglitazone. Diabetes. 2001;50(Suppl 2):A109. Abstract 437P.
38. King AB, Armstrong D. Comparison of the glucose and lipid effects of rosiglitazone (ROS) and pioglitazone (PIO) following conversion from troglitazone (TRO) treatment. Diabetes. 2001;50(Suppl 2):A120-A121. Abstract 482P.
39. Pentikainen PJ, Voutilainen E, Aro A, et al. Cholesterol lowering effect of metformin in combined hyperlipidemia: Placebo controlled double blind trial. Ann Med. 1990;22:307-312.